 This is a Phase II, multicenter, open-label clinical trial designed to determine the efficacy and safety of Brostallicin when administered once every 3 weeks in patients with myxoid liposarcoma with 12;16 translocation. The primary objective of this study is to determine the response rate following Brostallicin administration. 